Amid heightened market volatility driven by trade wars and geopolitical tensions, investors are turning their attention to resilient stocks, particularly those with robust dividend programs. Bristol Myers Squibb (BMY) stands out as a compelling option, offering a forward yield of 4.2%, significantly above the S&P 500 average of 1.2%. The pharmaceutical giant, known for its strong position in oncology and other therapeutic areas, is well-equipped to weather economic downturns due to consistent demand for its essential products.

Despite recent challenges, including patent expirations that have impacted revenue growth, Bristol Myers has a promising pipeline of innovative therapies launched since 2019, contributing to a 16% year-over-year sales increase in its growth portfolio. With a reasonable valuation at 9.5x forward earnings, well below the healthcare sector average, the company is positioned for potential upside as it navigates through a volatile market.

For market professionals, Bristol Myers represents a strategic investment opportunity that combines stability with the potential for dividend growth, making it an attractive choice in uncertain economic times.

Source: fool.com